218 related articles for article (PubMed ID: 21099212)
1. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
Saure C; Weigelt C; Schroeder T; Klärner V; Galonska L; Haas R; Kobbe G
Acta Haematol; 2010; 124(4):235-8. PubMed ID: 21099212
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.
De Blasio A; Rossi L; Zappone E; Ortu La Barbera E; Salvatori R; Pacilli M; Carbone A; Zaccarelli E; Papa A; Tomao S
Anticancer Drugs; 2013 Jul; 24(6):653-7. PubMed ID: 23698254
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
5. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Gregory KM; Rao KV; Armistead PM
Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
9. Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.
Patel B; Pearson H; Zacharoulis S
Pediatr Blood Cancer; 2015 Aug; 62(8):1477-80. PubMed ID: 25755177
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
Wagstaff AJ
Drugs; 2009; 69(3):319-26. PubMed ID: 19275275
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
14. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
[TBL] [Abstract][Full Text] [Related]
15. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
[TBL] [Abstract][Full Text] [Related]
16. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
17. Optimizing stem cell collection through CXCR4 antagonists.
Mahaseth H; Kaufman J
Front Biosci (Schol Ed); 2012 Jan; 4(2):611-9. PubMed ID: 22202080
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
19. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
20. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
